Inflammatory Diseases

• CDX-1189 - Renal Disease: Celldex is developing therapeutic human antibodies to a signaling molecule known as CD89 or Fcα receptor type I (FcαRI). CD89 is expressed by some white blood cells and leukemic cell lines, and has been shown to be important in controlling inflammation and tumor growth in animal models. Celldex has proprietary, fully human antibodies to CD89 in preclinical development. Depending upon the specific antibody used, anti-CD89 antibodies can either be activating and thus stimulate immune responses, or down-regulating and anti-inflammatory. For citations related to CDX-1189 click here.

• CDX-1135 – Renal Disease: Celldex is developing soluble Complement Receptor Type 1 (sCR1, TP10), a specific and potent inhibitor of complement activation, for use in renal disease indications. sCR1 has previously been in clinical trials and demonstrated a good safety profile and complement inhibition. sCR1 inhibits the classical, alternative and lectin pathways of complement at both early (C3 convertase) and late (C5 convertase) stages by down-regulating the activation of these cascades. sCR1 affects only activated complement and is not consumed, but can recycle in the inhibitory process. Because antigen-antibody complexes directly activate the classical pathway of complement causing local cytotoxicity and inflammation, complement inhibition with sCR1 is expected to ameliorate antibody-mediated graft rejection (AMR). Published preclinical studies of sCR1 in models of sensitized allograft rejection and of hyperacute xenograft rejection strongly support its use for AMR in renal transplantation. Further, certain rare renal diseases involve dysregulated complement and have been associated with mutations in complement proteins including Factor H and Membrane Cofactor Protein (MCP). sCR1 has similarities to Factor H and MCP in structure and function thus providing strong support for its potential efficacy in these diseases. For citations related to sCR1 click here